AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$BIO

Bio-Rad: Q3 Earnings Snapshot

Bio-Rad Laboratories reported Q3 net income of $458.6M, up from a loss last year. EPS was $17.02, with adjusted EPS at $2.65. Revenue reached $656.4M. Shares (BIO.B) are up 22% YTD and 25% over 12 months, trading at $379.50.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bio-Rad: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BIOBullishMed
01

Why it matters

Earnings beat may trigger analyst upgrades and short‑term buying pressure.

02

Market read

First‑report earnings data for a mid‑cap biotech equipment maker, likely to move the stock.

03

What to watch

Potential supply‑chain constraints for instrument components.

Relevance 8/10Novelty 8/10Timing: after‑hours release

Background

Bio‑Rad Laboratories is a leading provider of life‑science research and clinical diagnostics instruments.

Company-level read

Ticker impact

$BIOBullishHigh confidence
Context

Bio‑Rad reported Q3 net income of $458.6 M and EPS of $2.65, a turnaround from a loss a year ago.

Expected impact

upward pressure as the market prices in the earnings beat

Evidence & confidence

Quarterly profit and EPS beat expectations, plus a 22% YTD share gain, suggest strong buying interest.

Market effects

Sector

Boosts sentiment for the life‑science instrumentation sector.

Regional

Positive for US biotech and diagnostics stocks.

Global

Limited to investors tracking US biotech earnings.

Counterpoint

What could challenge this read

If guidance is weak, the rally could be short‑lived.

Key entities

  • company
    Bio‑Rad Laboratories Inc.

    US‑listed life‑science instrumentation firm.

Read at source← All news

StoryBio‑Rad posts Q3 2026 results with strong profit and modest revenue outlook

Also covered by

2 outlets

Related articles

$BIOHighAI 8/10

Bio-Rad (BIO) Q3 2026 Earnings Call Transcript

Bio-Rad reported Q3 2026 revenue of $656M, up 0.5% YoY. Gross margin expanded to 54.5%. Clinical Diagnostics and Life Science segments showed growth, with ddPCR instrument revenue up over 20%. The company expects challenges in academic, government, and APAC markets but remains optimistic about long-term ddPCR growth.

finance.yahoo.com
$BIOMedAI 8/10

Bio-Rad Laboratories Inc (BIO) (Q3 2026) Earnings Call Highlights: Return

Bio-Rad Laboratories reported Q3 2026 earnings, highlighting challenges in life science sales, academic funding, and China operations. Full-year revenue growth is guided between -3% and +0.5%. The company expects continued market softness but aims for positive growth in 2027. Key growth drivers include ddPCR instruments and diagnostics, with AI applications enhancing products and operations. The board is undergoing a refresh, and dialogue with Elliott Management is ongoing.

finance.yahoo.com
$BIOMedAI 8/10

What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call

Bio-Rad Laboratories (BIO) reported Q3 non-GAAP earnings of $2.65 per share, up from $2.26 a year earlier. The company reaffirmed its full-year revenue growth forecast of -3% to +0.5% and expects Q4 revenue to rise 5-6% sequentially. Bio-Rad aims for operating margins above 20% over time and plans to focus on positive revenue growth in 2027. Management discussed market pressures and strategic initiatives, including product launches and potential acquisitions.

finance.yahoo.com
$BIOHigh

Bio-Rad Reports Third-Quarter 2026 Financial Results

BIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Bio-Rad Reports Third -Quarter 2026 Financial Results HERCULES, Calif.—November 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results fo

SEC EDGAR 8-K
$BIOHighAI 8/10

Bio-Rad Reports Third-Quarter 2026 Financial Results

Bio-Rad reported Q3 2026 net sales of $656.4M, with GAAP net income of $458.6M. CEO Norman Schwartz cited growth in Clinical Diagnostics and strong demand for Droplet Digital PCR instruments. Non-GAAP operating margin was 12.8%. The company maintained its 2026 outlook, expecting non-GAAP revenue decline of 3.0% to growth of 0.5% and operating margin of 10.0% to 12.0%.

stocktitan.net